Based on evidence that MMP-2 is expressed in the bone marrow of myeloma patients and known roles for MMP-2 in the progression of skeletal malignancies [11, 12, 14, 16, 19], we hypothesized that inhibiting MMP-2 in myeloma would be an effective therapeutic strategy to prevent disease progression. This evidence concerns the gene MMP2 and plasma cell myeloma.